Navigation Links
Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
Date:11/2/2009

BOSTON, Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1. In the lead-in arms of the study, in which patients received a 4-week lead-in of PEGINTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) followed by the addition of narlaprevir, 85-87 percent of patients achieved rapid virologic response (RVR), compared to 58-75 percent of patients in the no lead-in narlaprevir arms and no patients in the PEGINTRON and REBETOL control arm. RVR, defined in this study as undetectable virus (HCV RNA) at week 4 of narlaprevir treatment, is recognized as an important predictor for achieving sustained virologic response. These interim results from the NEXT-1 study were reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.[1]

"These interim results, while preliminary, are very encouraging, and showed that narlaprevir has potent antiviral activity in hepatitis C," said John Vierling, M.D., professor of medicine and surgery, chief of hepatology, Baylor College of Medicine, Houston, and the lead investigator of the study. "In this study, once-daily narlaprevir greatly improved viral clearance at week 4 of treatment in genotype 1 hepatitis C infection compared to the control group. We look forward to further results from this ongoing study."

Importantly, patients in the lead-in narlaprevir arms also achieved improved rates of early virologic response (EVR), defined as undetectable virus at week 12 of treatment, with 85-87 percent of patients having undetectable
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... -- CipherHealth, a leading provider of innovations and solutions designed ... to the Nepalese American Nursing Association to donate money ... Nepal to aid in disaster ... addition to helping fund the travel costs for the ... medical supplies for the mission.  "Our ...
(Date:5/5/2015)... , May 5, 2015 Zimmer Holdings, Inc. ... today announced that its Board of Directors has approved the ... second quarter of 2015. The cash dividend of ... 14, 2015, to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
(Date:5/5/2015)... 5, 2015 Silver Creek Pharmaceuticals, Inc. announced ... (SBIR) grant from the National Institute of Health (NIH). ... San Francisco based biotechnology company that discovers ... damaged by disease. This award will be used to ... tissue following a heart attack. Silver Creek,s ...
Breaking Medicine Technology:Five Nurses and Medical Supplies En Route to Nepal With Donation Assistance from CipherHealth 2Silver Creek Pharmaceuticals Awarded NIH SBIR Grant for Smart Growth Factor Technology 2
... plc (LSE: SHP, NASDAQ: SHPGY ), the global ... rights to develop and market Resolor ® (prucalopride) in ... N.V.  Terms of the agreement have not been disclosed. ... portfolio in Europe and is approved for use in 33 ...
... BabyPing will unveil a new high ... - CES - this week. The new BabyPing high security ... their infant on iPhone, iPad or iPod Touch through cutting edge ... truly reassuring alternative to old-style monitors by using the latest in ...
Cached Medicine Technology:Shire Acquires US Rights to Resolor® (prucalopride) 2Shire Acquires US Rights to Resolor® (prucalopride) 3Shire Acquires US Rights to Resolor® (prucalopride) 4BabyPing Wi-Fi Baby Monitor for iOS Debuts at CES - the Next Generation of Baby Monitor is Here 2
(Date:5/5/2015)... (PRWEB) May 05, 2015 Private equity ... FZ LLC has announced that its dental stem cell ... Store-A-Tooth™ increased once again--in April, 2015 –and posted yet ... of increased record volume and represents a significant 54% ... dental stem cell biobank is conducted via the Store-A-Tooth ...
(Date:5/5/2015)... Indian Trail, NC (PRWEB) May 05, 2015 ... firm serving Indian Trail, Monroe, Matthews, Charlotte and surrounding ... in the field of accounting. This company provides assistance ... a priority as they prepare individual or corporate tax ... a system in the cloud that allows clients (and ...
(Date:5/5/2015)... May 05, 2015 AxoGen, Inc. ... on the $1.6 billion peripheral nerve repair market, reported ... ended March 31, 2015 compared to $3.14 million in ... adoption of our proprietary portfolio of nerve repair products ... AxoGuard® Nerve Protector – and our solid sales execution ...
(Date:5/5/2015)... 05, 2015 Hiliary Critchley, Senior ... present at the 24th Annual WEDI National ... MT in Scottsdale, AZ. WEDI, the Workgroup for ... authority on the use of health IT to ... National Director of Telemedicine for UnitedHealthcare will co-present ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 ... ) filed on behalf of men who ... their use of prescription testosterone replacement therapies ... multidistrict litigation underway in U.S. District Court, ... documents dated May 1st, defendants AbbVie, Inc., ...
Breaking Medicine News(10 mins):Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Optimity Advisors’ Hiliary Critchley, Telemedicine Expert, to Speak at WEDI Conference May 20th in Scottsdale, AZ 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4
... ... Provider Earns $1.6 Million in Rebates This Year, Highlights ... Redwood City Project, REDWOOD ... nation,s largest not-for-profit,health plan, will today celebrate significant energy efficiency upgrades,and solar installations ...
... Cardiac Science,Corporation (Nasdaq: CSCX ), a ... announced today that it will present at the,18th ... York City. The,Company,s presentation is scheduled for Monday, ... Hinson, president and chief executive officer, will,review the ...
... method for evaluating the eyes ability to distinguish object ... (AMD) could provide a more accurate way to assess ... with devices and training, according to a Canadian study. ... high-contrast illumination targets for testing spatial vision, which the ...
... Mack, Inc., a leading provider,of case management software ... care organizations, announced the Columbiana County (Ohio) Board ... its Q,Continuum System. Q Continuum System, CH ... contains a complete suite of functions,supporting "best in ...
... Hovione,s Technology,Transfer Center (TTC) in New Jersey has ... inspection was carried out by Ms. Joy R. Kozlowski-Klena ... and Research (CDER) and,lasted 3 days, starting on October ... issued. At the closing meeting, the inspector had several ...
... Nears, NEW YORK, Oct. 29 - An overwhelming ... issue with their,doctors despite recent visits, and an alarming ... are risk factors for dementia, according to,results of a ... the Alzheimer,s Foundation of America (AFA)., These findings ...
Cached Medicine News:Health News:The Healing Power of Green 2Health News:The Healing Power of Green 3Health News:Cardiac Science to Present at the 18th Annual CIBC World Markets Healthcare Conference 2Health News:Test for visual acuity could aid detection, rehabilitation of AMD 2Health News:Columbiana County Board of MR/DD Chooses Q Continuum(TM) System 2Health News:Columbiana County Board of MR/DD Chooses Q Continuum(TM) System 3Health News:FDA Inspects Hovione's Technology Transfer Center in New Jersey 2Health News:Survey Reveals Widespread Lack of Communication With Doctors About Memory Concerns 2Health News:Survey Reveals Widespread Lack of Communication With Doctors About Memory Concerns 3Health News:Survey Reveals Widespread Lack of Communication With Doctors About Memory Concerns 4
Full plate covers seal all 24 MicroAmp tubes...
An alternative sealing method for samples that are stored in 96-well plates after PCR. The mat is fully autoclavable and can be reused up to 50 times....
Inquire...
Pkg qty: box of 2 bags pack of 25 (Pack = Zippered Bag)...
Medicine Products: